AMR-001 / Lisata Therap - LARVOL DELTA

Genome-wide identification and characterization of NBS-encoding genes in the sweet potato wild ancestor Ipomoea trifida (H.B.K.). (PubMed, Open Life Sci) - "The qRT-PCR analysis revealed that IbNBS10, IbNBS20, IbNBS258, and IbNBS88 responded to stem nematode infection. These results provide critical proof for further characterization and analysis of NBS-encoding genes with important functions."

Journal • Infectious Disease

NeoStem announces geographic expansion of intellectual property coverage of AMR-001 to Russia (Globe Newswire) - "NeoStem...announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of the issuance of patent number 2011127184 in Russia. This patent...protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction ("AMI")....This incremental patent brings AMR-001's total worldwide patent coverage to eleven patents, and offers AMR-001 product protection in this important geography..."

Commercial • Patent • Acute Coronary Syndrome

NeoStem reports third Data Safety Monitoring Board review of PreSERVE AMI trial (NeoStem) - "NEOSTEM...announced that, on September 13, 2013, the Data Safety Monitoring Board (“DSMB”) recommended continuing the PreSERVE AMI Phase 2 clinical trial following a third interim data and safety review....AMR-001 is being evaluated for the preservation of heart function after a severe heart attack....to complete patient enrollment for this trial in 2013 with data read out 6-8 months after the last patient is infused.”"

Anticipated P2 data • DSMB • Enrollment status • Acute Coronary Syndrome

NeoStem announces geographic expansion of intellectual property coverage of AMR-001 to Canada (NeoStem) - "NeoStem...announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of a patent allowance in Canada."

Patent • Acute Coronary Syndrome

Amorcyte: Annual Report 12 (Amorcyte) - Anticipated patent expiries for acute coronary syndrome between 2026 and 2028

Anticipated patent expiry • Acute Coronary Syndrome

Amorcyte: Investor Presentation (Amorcyte) - "Phase 1 Trial Results Summary"; "Dose Response Correlated with Mobile CD34+ Cells"; "Patients dosed ≥ the threshold dose of 10 million cells showed significant improvement in perfusion"; "DSMB determined that no adverse events were related to therapy"; "Increased doses of CD34+/SDF-1 mobile cells reduced the size of infarct region by CMR"; "Y= Δ Infarct % LV Mass, X = Dose of SDF1 mobile CD34+ cells"; "Increasing doses of CD34+/ SDF-1 mobile cells reduced RTSS indicating improved perfusion Y= Δ RTSS, X = Dose of SDF1 mobile CD34 cells"

P1 data • Acute Coronary Syndrome

AMR-1: Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction (clinicaltrials.gov) - P1; N=31; Completed; Sponsor: Emory University; N=40 ➔ 31

Clinical • Enrollment change

AMR-1: Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction (clinicaltrials.gov) - P1; N=31; Completed; Sponsor: Emory University; Active, not recruiting ➔ Completed

Clinical • Trial completion